Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Otis W. Brawley"'
Autor:
Otis W. Brawley
Publikováno v:
Cancer. 127:1374-1376
Recent Patterns in Shared Decision Making for Prostate-Specific Antigen Testing in the United States
Autor:
Ann Goding Sauer, Stacey A. Fedewa, Ted Gansler, Robert A. Smith, Richard C. Wender, Ahmedin Jemal, Otis W. Brawley
Publikováno v:
The Annals of Family Medicine. 16:139-144
PURPOSE Previous studies report infrequent use of shared decision making for prostate-specific antigen (PSA) testing. It is unknown whether this pattern has changed recently considering increased emphasis on shared decision making in prostate cancer
Autor:
Otis W. Brawley
Publikováno v:
Cancer. 124:2890-2892
Autor:
Otis W. Brawley
Publikováno v:
JNCI Monographs. 2012:152-156
In the United States, prostate cancer is the most commonly diagnosed non-skin cancer and the second leading cause of cancer death. The American Cancer Society estimates that 241 740 American men will be diagnosed with the disease and 28 170 men will
Autor:
Otis W Brawley, H. Gilbert Welch
Publikováno v:
Annals of Internal Medicine. 169:134
Cancer screening is often recommended to patients believed to have a specific risk factor, such as prostate cancer screening for men who have a family history of the disease or melanoma screening f...
Publikováno v:
JAMA Internal Medicine. 177:1040
This study of National Health Interview Survey data evaluates recent patterns of prostate-specific antigen testing for prostate cancer screening in the United States
Autor:
Timothy J. Key, Lori M. Minasian, Zoran Culig, Bernd J. Schmitz-Dräger, Fritz H. Schröder, Jack A. Schalken, Freddie C. Hamdy, Jack Cuzick, Lars Holmberg, Rosalind A. Eeles, Powel H. Brown, Sven Perner, Harry G. Rittenhouse, Frank L. Meyskens, Howard L. Parnes, Bertrand Tombal, Hans-Peter Schmid, Timothy J Wilt, Michael Marberger, Arnulf Stenzl, Hans Lilja, Leslie G. Ford, Mangesh A. Thorat, Carlo La Vecchia, Chris Parker, Alicja Wolk, Otis W. Brawley, Gerald L. Andriole, Dragan Ilic
Publikováno v:
Lancet Oncology, 15, e484-92
Cuzick, J; Thorat, MA; Andriole, G; Brawley, OW; Brown, PH; Culig, Z; et al.(2014). Prevention and early detection of prostate cancer. The Lancet Oncology, 15(11), e484-e492. doi: 10.1016/S1470-2045(14)70211-6. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/99829759
Lancet Oncology, 15(11), E484-E492. Lancet Publishing Group
Lancet Oncology, 15, 11, pp. e484-92
Cuzick, J; Thorat, MA; Andriole, G; Brawley, OW; Brown, PH; Culig, Z; et al.(2014). Prevention and early detection of prostate cancer. The Lancet Oncology, 15(11), e484-e492. doi: 10.1016/S1470-2045(14)70211-6. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/99829759
Lancet Oncology, 15(11), E484-E492. Lancet Publishing Group
Lancet Oncology, 15, 11, pp. e484-92
Contains fulltext : 139211.pdf (Publisher’s version ) (Closed access) Prostate cancer is a common malignancy in men and the worldwide burden of this disease is rising. Lifestyle modifications such as smoking cessation, exercise, and weight control
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07d367cd74ea13c1e896ee7cacb739af
http://hdl.handle.net/2066/139211
http://hdl.handle.net/2066/139211
Autor:
Otis W. Brawley
Publikováno v:
Journal of the National Cancer Institute. 105(20)
Autor:
Polly Feigl, Otis W. Brawley, John Crowley, Brent A. Blumenstein, Charles A. Coltman, Ian M. Thompson, Barnett S. Kramer, Michael Wolf, Leslie G. Ford
Publikováno v:
Controlled Clinical Trials. 16:150-163
The PCPT is a chemoprevention trial of finasteride with a primary endpoint of biopsy-proven presence or absence of prostate cancer. A total of 18,000 healthy men, aged 55 years and older, will be randomized. Half will receive finasteride (5 mg/day) a